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Abstract The Jun dimerization protein 2 (JDP2) is a novel
member of the basic leucine zipper family of transcription
factors. JDP2 binds DNA as a homodimer and heterodimer with
ATF2 and Jun proteins but not with c-Fos proteins. JDP2
overexpression represses activating protein 1 transcription
activity. Whereas JDP2 mRNA and protein levels are stable
following different cell stimuli, JDP2 is rapidly phosphorylated
upon UV irradiation, oxidative stress and low levels of translation
inhibitor. The c-Jun N-terminal kinase phosphorylates JDP2
both in vitro and in vivo. JDP2 contains a putative consensus
JNK docking-site and a corresponding phosphoacceptor site.
Substitution of threonine 148 to an alanine residue blocks JNK-
dependent JDP2 phosphorylation. Our data indicate that JDP2
is a bona fide substrate for the c-Jun N-terminal kinase. The
precise role of JDP2 phosphorylation on its function is not yet
known. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The activating protein 1 (AP-1) is an immediate early tran-
scription factor composed of multiple protein families such as
the Jun, Fos and ATF [1,2]. AP-1 is an important transcrip-
tion factor in multiple cellular processes as diverse as cell
proliferation, di¡erentiation and apoptosis [1].
All AP-1 proteins contain a basic region responsible for
DNA binding followed by a leucine zipper motif (bZIP) im-
portant for homo- and heterodimerization between family
members. The Jun family is able to homodimerize as well as
heterodimerize with Fos and ATF family members [3,4]. Het-
erodimerization serves to increase their a⁄nity towards the
TPA response element (TRE) and modify their DNA binding
speci¢city. The AP-1 components are subjected to multiple
levels of regulatory mechanisms and modi¢cations that result
in dramatic changes in their transcription activity. In addition
to subunit exchange, the transcription of various AP-1 com-
ponents is regulated upon serum and growth factor stimula-
tion. More importantly, post-transcriptional modi¢cations
play a major role in the regulation of AP-1 activity [1,2].
The AP-1 components are subjected to phosphorylation by
multiple kinases such as the c-Jun N-terminal kinase (JNK)
[5,6] and the Fos regulating kinase (FRK), yet to be identi¢ed
[7]. The phosphorylation occurs at their transcription activa-
tion domain, which strongly potentiates their transcriptional
activity, presumably by facilitating interaction with CBP/p300
co-activators [8] and/or resulting in prolonged half-life [9,10].
In addition, casein kinase II phosphorylation of c-Jun inhibits
its DNA binding activity [11]. Recently, we have isolated a
novel member of the bZIP protein family designated: JDP2
[12]. JDP2 was isolated based on its ability to interact with
c-Jun bZIP domain. JDP2 contains a leucine zipper domain
that is most closely related to ATF3 [13] exhibiting 60% ami-
no acid homology. JDP2 is able to homodimerize and hetero-
dimerize with both Jun family members and ATF2 proteins
[14] but not with c-Fos proteins. JDP2 is able to bind both
TRE and CRE DNA binding elements, either as a homodimer
or heterodimer [12,14]. Unlike Fos proteins, JDP2 protein
levels remain unchanged following growth factor and serum
stimulation. JDP2 overexpression in ¢broblast cells results in
strong inhibition of AP-1 transcriptional activity. Recently,
we have showed that JDP2 can inhibit p53 induction as a
result of UV irradiation, resulting in inhibition of p53-medi-
ated apoptosis [15]. Since JDP2 has the potential to counter-
act AP-1 activity and the fact that AP-1 plays a central role in
signal transduction, we studied the regulation of JDP2 follow-
ing di¡erent cell stimuli. In this paper, we describe the process
whereby we identi¢ed that JDP2 undergoes rapid phosphory-
lation upon di¡erent stress conditions. We identi¢ed the JNK
as the kinase responsible for JDP2 phosphorylation and
mapped threonine 148 as the phosphoacceptor site.
2. Materials and methods
2.1. Cell culture
2.1.1. Cell culture and stimulation. Mouse ¢broblast cells (NIH
3T3), Rat intestinal cell lines IC18 and RI [16] and Rat1A cells
were grown in Dulbecco’s modi¢ed Eagle’s medium (DMEM) supple-
mented with 4.5 g/ml D-glucose 10% fetal calf serum in a 5% CO2
incubator.
2.1.2. Transfection. NIH 3T3 cells were transfected using lipofect-
amine (Gibco BRL Ltd.) with 6 Wg of DNA and 15 Wl of lipofectam-
ine according to the manufacturer’s instructions.
2.2. Cell stimulation
UV irradiation was applied using a 312 nm table lamp. The me-
dium was removed prior to 2 min UV irradiation. Typically the cells
were harvested 30 min following UV irradiation unless otherwise in-
dicated. Serum-starved cells grown in 1% serum for 24 h, were treated
with: anisomycin (50 ng/ml), H2O2 (5 mM), tumor promoter 12-O-
tetradecanoylphorbol-13-acetate (TPA, 50 ng/ml), for 30 min prior to
nuclear extract preparation [17].
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2.3. Potato acid phosphatase treatment
Nuclear cell extract (50 Wg) was incubated for 30 min at 37‡C with
40 Wg of potato acid phosphatase (Cat# 108227 Roche Inc.) in 10 mM
PIPES^HCl (pH 6.0) bu¡er.
2.4. Kinase induction
SRK expression plasmid encoding HA-JNK was transfected into
NIH 3T3 cells. 30 min before harvesting, cells were induced by UV
irradiation. Whole cell extract was prepared according to [5] and
immunoprecipitation, and an in vitro kinase assay was performed
with anti-HA antibodies (Babco Inc.) as described in [18]. In-gel ki-
nase assay was performed as described in [5].
2.5. Protein puri¢cation
GST and His fusion proteins were puri¢ed with glutathione (Sigma
Ltd.) or nickel (Qiagen Inc.) agarose beads, respectively according to
the manufacturer’s instructions. In principle, following elution with
5 mM glutathione and 100 mM EDTA, respectively, puri¢ed proteins
were dialyzed against PBS containing 10% glycerol. PGEX-kg-TAT
plasmid was a kind gift from Dr. Michael Olson. TAT-JDP2 proteins
were extracted and puri¢ed as described [19]. TAT-JDP2 was cleaved
by overnight digestion with thrombin (Sigma Cat# T7513) at 4‡C
followed by incubation with p-aminobenzamidine beads (Sigma
A-7155) for 1 h to remove the thrombin.
2.6. Protein detection
Immunoprecipitation and Western blot analysis were performed
with anti-HA monoclonal (12CA5) antibodies (Babco Inc.), anti-c-
Myc 9E11 monoclonal antibodies and anti-JDP2 antibodies [12]. All
incubations and washing steps were performed using 10% low fat milk
in phosphate bu¡er saline except for the incubation with anti-JDP2
antibodies where the bu¡er was supplemented with NaCl to a ¢nal
concentration of 300 mM and 0.1% Tween 20.
2.7. Plasmids
Mammalian His-JDP2 was expressed using the pCDNA 3.1 expres-
sion plasmid (Invitrogen Inc.); SRK expression vectors were previ-
ously described [18,20]. pET-His expression plasmids were based on
pET15b bacteria expression vector (Novagen Inc.).
Site-directed mutagenesis was performed using the Chameleon kit
(Stratagene Inc.) according to the manufacturer’s instructions and
using the appropriate oligonucleotides. The mutations were con¢rmed
by DNA sequencing. Bacterial histidine-tagged plasmids encoding
JDP2 deletion mutants were constructed by polymerase chain reaction
(PCR) approach with appropriate primers to result in frame fusion of
JDP2 with the pcDNA histidine-tag. DNA sequencing was performed
to verify that JDP2 is free from PCR mutations.
3. Results
Previous studies have shown that JDP2 protein levels are
stable following serum stimulation [12]. To examine the ex-
pression levels of JDP2 protein following di¡erent cell stimuli,
we exposed NIH 3T3 cells to phorbol ester treatments (TPA),
low levels of translational inhibitor anisomycin, oxidative
stress (H2O2) and UV irradiation 30 min prior to cell extrac-
tion (unless otherwise indicated). Nuclear cell extract prepared
from treated cells was separated by a long 12.5% SDS^PAGE
followed by Western blotting and incubation with anti-JDP2
antibodies. JDP2 typically migrates as a doublet band at a size
of 20^21 kDa (Fig. 1A). These bands may correspond to an
alternative ATG usage at the 5P-end of the transcript. Expres-
sion of JDP2 fused to an upstream ATG consensus sequence
appears as a single band (see for example Fig. 3D). JDP2
expression levels are unchanged following cellular treatments
by various stimuli. Following anisomycin, H2O2 treatments or
UV irradiation, slower migration of JDP2 cross-reactive band
was observed (Fig. 1A). Similar aberrant migration occurs in
all cell lines tested of mouse and rat origin (Fig. 1B) and
human origin (not shown). No change in migration was ob-
served upon TPA treatments and 5 min following UV irradi-
ation. In addition, nuclear extract prepared 24 h after UV
irradiation still showed the upshift in JDP2 migration (not
shown). To test the possibility that JDP2 aberrant migration
is due to phosphorylation, cell extract derived from UV-irra-
diated cells was treated with potato acid phosphatase and was
subjected to Western blot analysis using anti-JDP2 antibodies
(Fig. 1C). The migration of JDP2 protein following phospha-
tase treatment was identical to the corresponding protein de-
rived from unstimulated cells. These results suggest that JDP2
is phosphorylated upon di¡erent stress stimuli that are known
to activate the stress activating protein kinases, SAPK [21,22].
To test whether or not the JNK is able to phosphorylate
JDP2, we performed an in-gel kinase assay with either bacte-
rially puri¢ed GST-c-Jun or bacterially puri¢ed histidine-
tagged JDP2 proteins. In this assay the puri¢ed proteins are
polymerized within the separating gel. Whole cell extracts de-
rived from: untreated cells, TPA-induced, UV-irradiated and
anisomycin-treated cells were resolved by SDS^PAGE. Fol-
lowing electrophoresis, the gel was subjected to a denaturation
with 6 M urea followed by a stepwise renaturation protocol.
Subsequently, the gel was incubated with kinase bu¡er in the
Fig. 1. Stress stimuli induce changes in JDP2 migration. A: Serum-
starved NIH 3T3 cells were treated as indicated: TPA (50 ng/ml),
anisomycin (50 ng/ml), 5 mM H2O2 and UV irradiation (312 nm
for 2 min). Nuclear extract was prepared 30 min (otherwise as indi-
cated) following cell stimulation. Extract was separated by 16 cm
long 12.5% SDS^PAGE immobilized to Hybond (Amersham Inc.)
nitrocellulose membrane. Western blot analysis was performed using
anti-JDP2 as primary antibody and HRP-conjugated-protein-A fol-
lowed by chemiluminescent reaction and autoradiography. The
migration of JDP2 is indicated. B: The indicated cell lines were ex-
posed to UV irradiation 30 min prior to cell harvesting. NIH 3T3
stably transfected with JDP2 (NIH+JDP2) [15], IEC18 and RI [16].
Cell extract and Western blot analysis was performed as described
in A. C: Rat1A cells stably transfected with JDP2 wild type were
serum-starved (24 h, 1% serum) and UV-irradiated where indicated
(UV+). Nuclear extract (50 Wg) was treated with potato acid phos-
phatase (Phosph.+). All protein extracts were incubated at 37‡C for
30 min followed by separation by 12% SDS^PAGE and Western
blot analysis with anti-JDP2 antibodies.
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presence of [Q32P]ATP, dried and exposed to autoradiography
(Fig. 2A). The gels containing either GST-c-Jun (Fig. 2A, mid
panel) or His-JDP2 (Fig. 2A, right panel) exhibited a signi¢-
cant incorporation of radiolabelled phosphate in cell extract
derived from UV and anisomycin-treated cells but not from
extract-derived TPA-treated cells or non-treated cells. This
result suggests the presence of active kinases at position 46
and 55 kDa that are able to phosphorylate both c-Jun and
JDP2. The protein kinases that are consistent with this size
and activation signals may correspond to JNK1 and JNK2,
respectively. The 55 kDa kinase, JNK2, exhibits a stronger
signal with both GST-c-Jun and His-JDP2 which may re£ect
higher binding a⁄nity of this kinase to c-Jun [18] and may
suggest similar preference towards JDP2. The upper band
migrating at 70 kDa that appears in both gels may correspond
to an autophosphorylation of a constitutive kinase and is
readily observed in the gel where no substrate was added as
well (Fig. 2A, left panel). To test more directly the ability of
JDP2 to serve as JNK substrate, we performed an in vitro
kinase assay with immunopuri¢ed activated JNK. Cells were
transfected with plasmids encoding HA-JNK1 and subse-
quently cells were UV-irradiated 30 min prior to cell extrac-
tion. Anti-HA 12CA5 antibody was used to immunoprecipi-
tate HA-JNK1 followed by extensive washes. Immunopuri¢ed
HA-JNK1 was incubated with either bacterially puri¢ed His-
JDP2 or GST-c-Jun in the presence of [Q-32P]ATP. Following
a kinase reaction the extract was separated by SDS^PAGE,
Coomassie blue-stained, dried and exposed to autoradiogra-
phy (Fig. 2B). The results shows that JNK1 is able to e⁄-
ciently phosphorylate His-JDP2 at levels comparable to the
phosphorylation obtained with puri¢ed GST-c-Jun. Control
extracts derived from cells transfected with either an empty
expression vector or kinase-inactive JNK1 [6] (HA-JNK-APF)
were unable to phosphorylate either His-JDP2 or GST-c-Jun,
indicating that JDP2 is a direct JNK substrate. Similar anal-
ysis with HA-ERK2 resulted in no His-JDP2 phosphorylation
(not shown), suggesting that JDP2 is a bona ¢de substrate for
JNK but not for ERK. This is consistent with the fact that
TPA treatment did not induce the typical upshift that is ob-
served following JNK activation (Fig. 1).
In order to map the JNK phosphoacceptor site within
JDP2, we prepared JDP2 bacteria expression plasmids encod-
ing histidine-tagged JDP2 deletion mutants in which either the
N-terminal or the C-terminal domains were deleted (Fig. 3A).
Proteins were puri¢ed by nickel agarose and used in an in
vitro kinase assay with activated HA-JNK2 (Fig. 3B). Trun-
cation of JDP2 N-terminal domain completely retained its
ability to undergo phosphorylation by JNK2 (Fig. 3B). In
contrast, deletion of the C-terminal domain resulted in a com-
plete loss in JDP2 phosphorylation. This indicates that JDP2
phosphoacceptor site is located within the C-terminal domain.
The JNKs are proline-directed kinases, thus phosphorylate
substrates on either a serine or a threonine residue followed
by a proline residue. Within JDP2 C-terminal domain, threo-
nine 148 is followed by a proline residue. To test whether or
not threonine 148 is a JNK phosphoacceptor site, we used
site-directed mutagenesis to convert threonine 148 to an ala-
nine residue (JDP2-T148A). Bacterially puri¢ed JDP2-mutant
protein harboring T148A was unable to undergo phosphory-
lation by activated JNK2 in vitro (Fig. 3C). In order to dem-
onstrate that threonine 148 serves as JNK phosphoacceptor
site in vivo, we established a NIH 3T3 stable cell line express-
ing either His-JDP2 wild type or His-JDP2-T148A mutant.
Histidine-tagged JDP2 migrates signi¢cantly slower (25 kDa)
as compared to the endogenous protein and therefore can be
easily distinguished from the endogenous JDP2 protein. Cells
were subjected to UV irradiation and nuclear extracts were
separated by SDS^PAGE followed by Western blot analysis
Fig. 2. In vitro phosphorylation of bacterially puri¢ed JDP2 by the stress activated protein kinase, JNK1. A: Cell extracts derived from NIH
3T3 cells treated as indicated were separated by 10% SDS^PAGE. The separating gels were polymerized in the absence (no substrate, left pan-
el) or in the presence of either bacterially puri¢ed (40 Wg/ml) GST-c-Jun (GST-c-Jun, middle panel) or bacterially puri¢ed His-JDP2 (right pan-
el). After electrophoresis, the gels were treated as described in [5], dried and exposed to autoradiography for 12 h. B: Bacterially puri¢ed His-
JDP2 was used as a substrate in an in vitro kinase assay using immunopuri¢ed activated HA-JNK1 protein. Coomassie brilliant blue staining
(left panel) and [Q-32P]ATP incorporation is shown (right panel). Cell extracts corresponding to either vector transfected (SRK) or the indicated
HA-tagged kinases were used in an in vitro kinase assay using either bacterially puri¢ed His-tagged JDP2 (His-JDP2) or bacterially puri¢ed
GST-c-Jun. The immunopuri¢ed protein corresponding to the inactive kinase HA-JNK1-APF mutant [6] (JNK*) was used in the kinase assay
(lanes 9 and 12).
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with anti-JDP2 antibodies (Fig. 3D). The endogenous JDP2
protein exhibited the typical slower migrating band following
UV irradiation as well as cell extract derived from His-JDP2
wild type expressing cells. In contrast, no change in the mi-
gration of His-JDP2 T148A was observed following UV irra-
diation (Fig. 3D). This result indicates that threonine 148
serves as the JNK phosphoacceptor site in vivo.
4. Discussion
Although the JNK kinase has attracted the attention of
many investigators, the substrates available for these enzymes
are rather limited. So far, c-Jun, ATF2, Sap-1a, ELK1,
c-Myc, Bcl2, p53, and NFAT4 are the best substrates charac-
terized [22,23]. As for c-Jun [6], ATF2 [24] Sap-1a [25] and
ELK1 [26], it was demonstrated that JNK phosphorylation is
within their transcriptional activation domain, resulting in
potentiation of their transcriptional activity. As for NFAT4,
its phosphorylation was found to counteract calcineurin phos-
phatase action, resulting in translocation of NFAT4 to the
cytoplasm and thereby inactivating NFAT4 action [27].
Two additional JNK substrates, p53 [28] and Bcl2 [29] were
initially described as substrates with no obvious function. In
the case of p53, it was recently demonstrated that JNK-de-
pendent p53 phosphorylation targets p53 to ubiquitination
and degradation [30], whereas, for Bcl2 it was demonstrated
that JNK phosphorylation inactivates its anti-apoptotic activ-
ity [31].
In this paper, we described the identi¢cation of JDP2 as a
novel substrate for the stress activating kinase JNK. Threo-
nine 148 of JDP2 is the phosphoacceptor site and mutation of
this site completely abrogated JDP2 phosphorylation both in
vitro and in vivo. Endogenous JDP2 protein undergoes phos-
phorylation under di¡erent stress conditions such as: UV ir-
radiation, oxidative stress and anisomycin treatments. It has
been shown that the JNK phosphoacceptor site is distinct
from its docking-site [23,32]. The consensus JNK docking-
site found in the c-Jun delta region includes KXXK/
RXXXXLXL. Indeed, such a sequence is present upstream
of the JDP2 phosphoacceptor site and resides within the
JDP2 leucine zipper motif. The importance of this domain
for JDP2 phosphorylation is currently under investigation.
Since JDP2 function is clearly distinct from all the above-
mentioned substrates and serves as a transcriptional repressor,
the role of JDP2 phosphorylation is clearly distinct and yet to
be determined.
Using in vitro analysis (not shown), we failed to detect
di¡erences in DNA binding and association with JDP2 pro-
tein partners. One possibility could be that we used acidic
residues to mimic JDP2 phosphorylation. Although acidic res-
idue substitutions have been shown in several cases to mimic
protein phosphorylation events [33^36], it may be that JDP2
phosphorylation could not, as was already demonstrated in
CREB phosphorylation on serine 133, where a negative
charge could not mimic phosphorylated CREB activity [37].
Moreover, since JDP2 was shown to bind to multiple DNA
elements such as: CRE, TRE and CAAT sequences [12,38],
one cannot exclude the possibility that binding to a speci¢c
DNA binding site, yet to be identi¢ed, is subject to di¡erential
regulation by JDP2 phosphorylation. This also may explain
our failure to detect di¡erences in JDP2 activity using reporter
gene assays in which the reporter gene is placed under the
control of consensus AP-1 binding sites that may not neces-
sarily be the actual physiological JDP2 targets. With the re-
cent advances in DNA array-based techniques one can better
de¢ne the natural targets for a speci¢c transcription factor.
For example, the Wilms tumor suppressor, WT1, in transient
transfection assays represses transcription from multiple DNA
elements. However, using a high-density oligonucleotide mi-
croarrays technique, WT1 was demonstrated to directly acti-
vate transcription from the amphiregulin promoter [39]. WT1
activity is performed via binding to a high-a⁄nity site within
the amphiregulin promoter suggesting that WT1 may function
as a transcriptional activator depending on the promoter
tested.
In summary: we have shown that JDP2 serves as a bona
¢de substrate for the stress activating kinase, JNK. The phos-
phorylation occurs on threonine 148. Substitution of threo-
Fig. 3. Threonine 148 is JNK phosphoacceptor site in vitro and in
vivo. A: Schematic diagram describing the deletion constructs used.
The basic region (Basic), the leucine zipper motif (L) and the threo-
nine-proline (TP) are indicated. The numbers on the top represent
the amino acid in JDP2 in respect to the truncation performed.
B: Bacterially puri¢ed His-tagged JDP2 proteins corresponding to
wild type (JDP2), C-terminal truncation (JDP2vC) and N-terminal
truncation (JDP2vN) were used in in vitro kinase assay as described
in Fig. 2B. The autoradiograph of [Q-32P]ATP incorporation follow-
ing the kinase reaction is shown. C: Bacterially puri¢ed TAT-JDP2
wild type protein and T148A mutant protein (2 Wg) were used in an
in vitro kinase assay as described in Fig. 2B. The autoradiograph of
[Q-32P]ATP incorporation following the kinase reaction is shown.
D: NIH 3T3 cells were stably transfected with a plasmid encoding
either His-tagged JDP2 wild type (JDP2-wt) or His-JDP2-T148A. A
NIH 3T3 cell line containing an empty pcDNA vector alone was
used as a control (Vec.). Cells were either untreated or UV-irradi-
ated 30 min prior to nuclear extract preparation. The extract was
separated by 12.5% SDS^PAGE followed by Western blotting.
JDP2 protein was detected using anti-JDP2 antibodies followed by
chemiluminescent reaction and autoradiography. The migration of
the endogenous JDP2 and the transfected His-JDP2 is indicated.
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nine 148 to an alanine residue abrogates JDP2 phosphoryla-
tion. The conservation of this site among di¡erent species and
the rapid and persistent phosphorylation may suggest that
JDP2 phosphorylation may have an important functional
role which is yet to be identi¢ed.
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